Overview of Dr. Chung
David Chung, MD, based in New York, is a specialist in Oncology with a subspecialty in Hematologic Oncology. His education includes a residency in Internal Medicine at UCLA David Geffen School of Medicine/UCLA Medical Center from 2001-2004, a fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center from 2004-2008, and a medical degree from Georgetown University School of Medicine (Class of 2001). Dr. Chung has expertise in immunotherapy, hematologic oncology, bone marrow transplantation, plasma cell myeloma, and multiple myeloma. He has published extensively in the field and has been involved in multiple clinical trials. Dr. Chung's notable contributions have been recognized with numerous awards, including the Myeloma Crowd Research Award and the Clinical Investigation Award from Experimental Therapeutics Center, MSKCC, among others.
Office
530 East 74th Street
New York, NY 10021
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2008
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2001 - 2004
Georgetown University School of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2002 - Present
FL State Medical License 2021 - Present
CT State Medical License 2023 - 2025
NJ State Medical License 2020 - 2025
NY State Medical License 2004 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Myeloma Crowd Research Award Myeloma Crowd Foundation, 2018
- Clinical Investigation Award Experimental Therapeutics Center, MSKCC, 2014
- Translational New Investigator Award Department of Defense, 2011
- Join now to see all
Clinical Trials
- CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Start of enrollment: 2014 Jan 31
- Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant Start of enrollment: 2016 Dec 13
- Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) Start of enrollment: 2016 Jul 01
Publications & Presentations
PubMed
- 37 citationsFactors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer C...Melissa Pozotrigo, Nelly G. Adel, Heather Landau, Alexander M. Lesokhin, Nikoletta Lendvai
Bone Marrow Transplantation. 2013-08-01 - 1 citationsRegulation of the hematopoietic stem cell pool by C-Kit-associated trogocytosis.Xin Gao, Randall S Carpenter, Philip E Boulais, Dachuan Zhang, Christopher R Marlein
Science. 2024-08-09 - 44 citationsDynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.Benjamin Diamond, Neha Korde, Alexander M. Lesokhin, Eric L. Smith, Urvi A Shah
The Lancet. Haematology. 2021-06-01
Abstracts/Posters
- Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...David J. Chung, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...David J. Chung, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...David J. Chung, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma...2021 ASH Annual Meeting - 12/13/2021
- Evaluation of Tumor Vaccine Generation in a Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant (AutoHCT) Followed By Lenalidomide Maintenanc...2020 Transplantation & Cellular Therapy Meetings, Orlando, FL - 2/2020
- Stem Cell Mobilization and Autograft Purity with Novel Induction Regimens in Multiple Myeloma17th International Myeloma Workshop, Boston, MA - 10/2019
- Join now to see all
Press Mentions
Potential New Approach to Enhancing Stem-Cell TransplantsAugust 8th, 2024
Professional Memberships
- Member
- Member
- American Society for Blood and Marrow TransplantationMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
